



秋冬新品
全館滿1500現享88折

ZALORA
TAIWAN
立即買

- News
 - Articles
 - Videos
 - Images
 - Books
 - Reference
-
- Health & Medicine
 - Mind & Brain
 - Plants & Animals
 - Earth & Climate
 - Space & Time
 - Matter & Energy
 - Computers & Math
 - Fossils & Ruins

Science News

... from universities, journals, and other research organizations

- Save
- Email
- Print
- Share

Novel 'Antisense' Therapies Protect Primates from Lethal Ebola and Marburg Viruses

ScienceDaily (Aug. 23, 2010) — New studies show that treatments targeting specific viral genes protected monkeys infected with deadly Ebola or Marburg viruses. Furthermore, the animals were protected even when therapeutics were administered one hour after exposure -- suggesting the approach holds promise for treating accidental infections in laboratory or hospital settings.

Share This:

5
 7
 0
 17

See Also:

- Health & Medicine**
- Viruses
 - HIV and AIDS
 - Infectious Diseases
- Plants & Animals**
- Virology
 - Microbes and More
 - Monkeys
- Reference**
- Ebola
 - Tropical disease
 - Antiviral drug
 - Human parainfluenza viruses

The research, which appears in the August 22 online edition of the journal *Nature Medicine*, was conducted by the **U.S. Army Medical Research Institute of Infectious Diseases** in collaboration with AVI BioPharma, a Washington-based biotechnology firm.

Working with a class of compounds known as antisense phosphorodiamidate morpholino oligomers, or **PMOs**, scientists first performed a series of studies with mouse and guinea pig models of **Ebola** to screen various chemical variations. They arrived at a **therapy known as AVI-6002**, which demonstrated a survival rate of **better than 90 percent** in animals **treated either pre- or post-exposure**.

Encouraged by these results, the team conducted "proof of concept" studies in which 9 rhesus monkeys were challenged with lethal Ebola virus. Treatment was initiated 30-60 minutes after exposure to the virus. In these studies, 5 of 8 monkeys survived, while the remaining animal was untreated. Further experiments, including a multiple-dose evaluation, also yielded promising results, with 3 of 5 monkeys surviving in each of

the **AVI-6002** treatment groups when they received a dose of 40 mg per kg of body weight.

According to first author Travis K. Warren of **USAMRIID**, antisense drugs are useful against viral diseases because they are designed to enter cells and eliminate viruses by preventing their replication. **The drugs act by blocking critical viral genetic sequences**, essentially giving the infected host time to mount an **immune response** and **clear the virus**.

Ebola and Marburg cause hemorrhagic fever with case fatality rates as high as 90 percent in humans. The viruses, which are infectious by aerosol (although more commonly spread through blood and bodily fluids of infected patients), are of concern both as global health threats and as potential agents of biological warfare or terrorism. Currently there are no available vaccines or therapies. Research on both viruses is conducted in Biosafety Level 4, or maximum containment, laboratories, where investigators wear positive-pressure "space suits" and breathe filtered air as they work.

The **USAMRIID** team next turned its attention to **Marburg virus**, again screening various compounds in mice and guinea pigs to select a candidate for further testing. They settled upon **AVI-6003**, a drug that consistently conferred a high degree of efficacy (better than 90 percent survival) in both models.

Ads by Google

Viral Research Tools — Proteins, Antibodies, ELISA Kits For Flu, RSV, CMV, HIV Viruses ... > www.?.?Sino?Biological?.com

Influenza Hemagglutinin — Recombinant HA proteins from > 80 flu strains; plus antibodies & more ... > www?.immune-tech?.com

Find Cancer Treatment — Fight against life threatening cancer with best surgeons in Korea ... > kmhglobal?.com


??????? ??? — ???????,????????? ??????,????????? ... > www?.hcmc?.url?.tw

What Happens When You Die — New scientific theory says death isn't the end ... > ?Robert?Lanza?.com

Related Stories

 **Receptor for Ebola Virus Identified** (May 3, 2011) — Researchers have identified a cellular protein that acts as a receptor for Ebola virus and Marburg virus. Furthermore, the team showed that an antibody, which binds to the receptor protein, is able ... > [read more](#)

Small Molecules May Prevent Ebola Infection (Jan. 20, 2011) — Scientists report they've discovered small molecules that appear to bind to the outer protein coat of the Ebola virus, possibly blocking the virus from entering human cells. The finding may open new ... > [read more](#)

 **Experimental Marburg Vaccine Prevents Disease Two Days After Infection** (June 18, 2010) — An experimental vaccine developed to prevent outbreaks of Marburg hemorrhagic fever continues to show promise in monkeys as an emergency treatment for accidental exposures to the virus that causes ... > [read more](#)

Experimental Treatment Protects Monkeys from Lethal Ebola Virus Post-Exposure (May 29, 2010) — Scientists using tiny particles of genetic material to interfere in the replication process of the deadly Ebola virus have successfully prevented monkeys exposed to that virus from dying of ... > [read more](#)

 **'Ebola Cousin' Marburg Virus Isolated From African Fruit Bats** (Aug. 2, 2009) — Infection with Marburg virus and the related Ebola virus can produce severe disease in people, with fever and bleeding. During outbreaks, as many as 90 percent of those infected have died. The ... > [read more](#)

New Ebolavirus Vaccine Protects Against Lethal Infection in Animal Models (Apr. 23, 2009) — A new experimental Ebola vaccine is one step closer to realization, having proven its ability to protect against lethal infections in animal ... > [read more](#)

Vaccine For Ebola Virus Successful In Primates (Mar. 31, 2008) — One of the world's deadliest diseases, caused by the Ebola virus, may finally

Just In:
Trigger for Explosive Volcanic Eruptions

▶ [more breaking science news](#)

Social Networks

Recommend ScienceDaily on **Facebook**, **Twitter**, and **Google +1**:

Like Tweet 17.1K +3776 Recommend this on Google
 You and 39,470 others like this. 39,470 people like this. Sign
 Follow 44K followers

Other bookmarking and sharing tools:

| 46.2K

Breaking News

... from NewsDaily.com

- ▶ Soyuz rocket deploys two Galileo satellites 
- ▶ NASA in nasal spray deal to combat motion sickness
- ▶ Satellite burns up following SpaceX rocket glitch
- ▶ NASA's Mars rover finds rock with Earth-like chemistry
- ▶ Space shuttle Endeavour met with awe on trip through Los Angeles
- ▶ A diamond bigger than Earth?
- ▶ Citing privacy concerns, U.S. panel urges end to secret DNA testing

Investigators conducted two pilot studies in cynomolgus monkeys to assess the efficacy of AVI-6003 against lethal challenge with Marburg virus. As with the Ebola studies, treatments were initiated 30-60 minutes after infection. All 13 animals receiving AVI-6003 survived. Additional research provided important information about the optimal therapeutic dose range of the compound, with a 40 mg per kg body weight dose protecting 100 percent of the monkeys following challenge.

"This report of successful early post-exposure treatment of filovirus hemorrhagic fever is significant on its own," said Colonel John P. Skvorak, USAMRIID commander, "but the drug characteristics of these PMOs also support investigation of potentially broader therapeutic applications."

Senior author Sina Bavari said USAMRIID has been collaborating with AVI BioPharma since 2004. In February of that year, an Institute scientist working in a Biosafety Level 4 laboratory stuck her thumb with a needle while treating Ebola-infected mice with antibodies. As a precaution, USAMRIID medical experts recommended the investigator be isolated for 21 days to ensure that she had not been infected.

Coincidentally, earlier that very day, Dr. Patrick Iversen from AVI BioPharma had presented a seminar at USAMRIID concerning the efficacy of novel antisense drugs against a range of viruses. When he found out that a USAMRIID scientist had potentially been exposed to Ebola virus, the company volunteered to design and synthesize compounds against the virus to treat her if the need arose.

The team at AVI worked for four straight days to generate human-grade anti-Ebola compounds. In the meantime, their regulatory staff worked with USAMRIID physicians to gain emergency approval from the U.S. Food and Drug Administration to use the compounds if necessary. Five days after the exposure, AVI delivered the compounds to USAMRIID's medical team.

Fortunately, the scientist had escaped infection with Ebola virus, so the compounds were never used. However, USAMRIID went on to test them in animal models, and has been collaborating with AVI ever since.

According to the authors, the investigational new drug applications (IND) for AVI-6002 and AVI-6003 have been submitted to the U.S. Food and Drug Administration, and they are now open to proceed with clinical trials.

Collaborating on the study were Travis K. Warren, Jay Wells, Kelly S. Donner, Sean A. Van Tongeren, Nicole L. Garza, Donald K. Nichols, Lian Dong, and Sina Bavari of USAMRIID; Kelly L. Warfield and Dana L. Swenson, formerly of USAMRIID; and Dan V. Mourich, Stacy Crumley, and Patrick L. Iversen of AVI BioPharma.

Share this story on **Facebook**, **Twitter**, and **Google**:



Other social bookmarking and sharing tools:



Story Source:

The above story is reprinted from materials provided by **US Army Medical Research Institute of Infectious Diseases**, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

1. Travis K. Warren, Kelly L. Warfield, Jay Wells, Dana L. Swenson, Kelly S. Donner, Sean A. Van Tongeren, Nicole L. Garza, Lian Dong, Dan V. Mourich, Stacy Crumley, Donald K. Nichols, Patrick L. Iversen and Sina Bavari. **Advanced antisense therapies for postexposure protection against lethal filovirus infections.** *Nature Medicine*, 2010; DOI: [10.1038/nm.2202](https://doi.org/10.1038/nm.2202)

Need to cite this story in your essay, paper, or report? Use one of the following formats:

APA US Army Medical Research Institute of Infectious Diseases (2010, August 23). Novel

be preventable thanks to US and Canadian researchers, who have successfully tested several Ebola vaccines in primates and ... > [read more](#)

Combination Vaccine Protects Monkeys From Ebola And Marburg Viruses (Feb. 27, 2008) — An experimental, combination vaccine against ebola and Marburg viruses using virus-like particles provides complete protection against infection in monkeys. Traditionally vaccines against viral ... > [read more](#)

Ads by Google

- [TutorABC???????? — ??????????????,????? ? ?!????45??,????????? ... > \[www.tutorabc.com\]\(http://www.tutorabc.com\)](#)
- [?????? ????? — ???DVD?3C??,?????????, 10? ?????????,?????????! ... > \[www.books.com.tw\]\(http://www.books.com.tw\)](#)
- [Club Med??-???? — 2012' Club Med????????? , ??????????Club Med????? ... > \[www?.Perfect?.com?.tw\]\(http://www.Perfect.com.tw\)](#)
- [????--???? — ?????,????????, ?????,????? ???? ... > \[www?.shihchen?.com\]\(http://www.shihchen.com\)](#)

- [Work just beginning as drugmakers put Nobel discoveries to test](#)
- [more science news](#)

In Other News ...

- [Obama touts benefits of auto bailout as debate looms](#)
- [Al Qaeda leader Zawahiri calls for more Mohammad film protests](#)
- [Finance leaders back EU, U.S. to-do list to shield growth](#)
- [Blind Chinese activist says nephew could face unfair trial](#)
- [Shot fired into Obama campaign office in Denver](#)
- [Gates, Annan show sentencing support for convicted insider Gupta](#)
- [U.S. intelligence hurt when Libya base was abandoned](#)
- [Microsoft to sue Google with Motorola in German patent row](#)
- [more top news](#)

Copyright Reuters 2008. See [Restrictions](#).

Free Subscriptions ... from *ScienceDaily*

Get the latest science news with our free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

- [Email Newsletters](#)
- [RSS Newsfeeds](#)

Feedback ... we want to hear from you!

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?

Your Name:

Your Email:

Comments:

Click button to submit feedback:



MLA 'antisense' therapies protect primates from lethal Ebola and Marburg viruses. *ScienceDaily*. Retrieved October 13, 2012, from <http://www.sciencedaily.com/releases/2010/08/100822150645.htm>

Note: If no author is given, the source is cited instead.

Disclaimer: *This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.*

Search ScienceDaily

Number of stories in archives: 125,555

Find with keyword(s):

Enter a keyword or phrase to search ScienceDaily's archives for related news topics, the latest news stories, reference articles, science videos, images, and books.

[About ScienceDaily®](#) | [Editorial Staff](#) | [Awards & Reviews](#) | [Contribute News](#) | [Advertise With Us](#) | [Privacy Policy](#) | [Terms of Use](#)

Copyright © 1995-2012 ScienceDaily LLC — All rights reserved — Contact: editor@sciencedaily.com

Note: This web site is not intended to provide medical advice, diagnosis or treatment.

Part of the iVillage Your Total Health Network